Luo Wenjie, Dou Fei, Rodina Anna, Chip Sophorn, Kim Joungnam, Zhao Qi, Moulick Kamalika, Aguirre Julia, Wu Nian, Greengard Paul, Chiosis Gabriela
Laboratory of Molecular and Cellular Neuroscience, The Rockefeller University and Fisher Foundation for Alzheimer's Disease, New York, NY 10021, USA.
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9511-6. doi: 10.1073/pnas.0701055104. Epub 2007 May 21.
Neurodegeneration, a result of multiple dysregulatory events, is a lengthy multistep process manifested by accrual of mutant variants and abnormal expression, posttranslational modification, and processing of certain proteins. Accumulation of these dysregulated processes requires a mechanism that maintains their functional stability and allows the evolution of the neurodegenerative phenotype. In malignant cells, the capacity to buffer transformation has been attributed to heat-shock protein 90 (Hsp90). Although normal proteins seem to require limited assistance from the chaperone, their aberrant counterparts seem to be highly dependent on Hsp90. Whereas enhanced Hsp90 affinity for mutated or functionally deregulated client proteins has been observed for several oncoproteins, it is unknown whether Hsp90 plays a similar role for neuronal proteins and thus maintains and facilitates the transformed phenotype in neurodegenerative diseases. Tauopathies are neurodegenerative diseases characterized by aberrant phosphorylation and/or expression of Tau protein, leading to a time-dependent accumulation of Tau aggregates and subsequent neuronal death. Here, we show that the stability of p35, a neuronal protein that activates cyclin-dependent protein kinase 5 through complex formation leading to aberrant Tau phosphorylation, and that of mutant but not WT Tau protein is maintained in tauopathies by Hsp90. Inhibition of Hsp90 in cellular and mouse models of tauopathies leads to a reduction of the pathogenic activity of these proteins and results in elimination of aggregated Tau. The results identify important roles played by Hsp90 in maintaining and facilitating the degenerative phenotype in these diseases and provide a common principle governing cancer and neurodegenerative diseases.
神经退行性变是多种调节异常事件的结果,是一个漫长的多步骤过程,表现为突变变体的累积以及某些蛋白质的异常表达、翻译后修饰和加工。这些调节异常过程的积累需要一种机制来维持其功能稳定性,并允许神经退行性表型的演变。在恶性细胞中,缓冲转化的能力归因于热休克蛋白90(Hsp90)。虽然正常蛋白质似乎只需要伴侣蛋白提供有限的帮助,但其异常对应物似乎高度依赖Hsp90。虽然已经观察到几种癌蛋白对突变或功能失调的客户蛋白具有增强的Hsp90亲和力,但尚不清楚Hsp90是否对神经元蛋白起类似作用,从而在神经退行性疾病中维持并促进转化表型。tau蛋白病是一类神经退行性疾病,其特征是tau蛋白异常磷酸化和/或表达,导致tau聚集体随时间积累并随后导致神经元死亡。在这里,我们表明,p35(一种通过形成复合物激活细胞周期蛋白依赖性蛋白激酶5导致异常tau磷酸化的神经元蛋白)以及突变型而非野生型tau蛋白的稳定性在tau蛋白病中由Hsp90维持。在tau蛋白病的细胞和小鼠模型中抑制Hsp90会导致这些蛋白的致病活性降低,并导致聚集的tau蛋白消除。这些结果确定了Hsp90在维持和促进这些疾病的退行性表型中所起的重要作用,并提供了一个支配癌症和神经退行性疾病的共同原则。